next five years.
* In the quarter, Abbott received five key regulatory approvals:
HUMIRA for psoriasis and for juvenile rheumatoid arthritis,
Simcor(R) for cholesterol, and the FreeStyle Freedom Lite(TM) and
FreeStyle Navigator(R) glucose monitoring systems.
"Abbott started 2008 with a strong first quarter, following
double-digit sales and earnings growth last year," said Miles D. White,
chairman and chief executive officer, Abbott. "In addition, we received
five key new product approvals during the quarter. The continued
productivity of our late-stage pipeline, combined with the underlying
strength of our broad mix of businesses, gives us a high level of
confidence in our future growth outlook."
The following is a summary of first-quarter 2008 sales.
Sales Summary - Impact of
Quarter Ended 3/31/08 1Q08 % Change Exchange on
($ millions) vs. 1Q07 % Change
Total Sales $6,766 13.8 5.5
Total U.S. Sales $3,043 3.7 (a) ---
Total International Sales $3,723 23.6 10.9
Worldwide Pharmaceutical Sales $3,854 14.3 (a) 5.9
U.S. Pharmaceuticals $1,752 3.6 (a) ---
International Pharmaceuticals $2,102 25.1 11.9
Worldwide Nutritional Sales $1,110 10.8 3.0
U.S. Nutritionals $583 3.0 ---
International Nutritionals $527 20.8 6.9
Worldwide Diagnostics Sales (b) $832 17.1 8.1
U.S. Diagnostics $211 4.6
'/>"/>
| SOURCE Abbott Copyright©2008 PR Newswire. All rights reserved |